Endocrine orbitopathy - Current diagnosis and treatment;Endokrine orbitopathie - Aktuelle diagnostik und therapie

Medizinische Klinik

Volumn 103, Issue 10, 2008, Pages 717-728

  Ponto, Katharina A ^c   Kahaly, George J ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; METHYLPREDNISOLONE; THIAMAZOLE;

ANTIOXIDANT ACTIVITY; ARTICLE; DIAGNOSTIC PROCEDURE; ENDOCRINE OPHTHALMOPATHY; EYE SURGERY; FIBROBLAST; IMMUNOSUPPRESSIVE TREATMENT; MORPHOLOGY; PATHOGENESIS; RISK FACTOR;

ADULT; ANTITHYROID AGENTS; COMBINED MODALITY THERAPY; DECOMPRESSION, SURGICAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHIMAZOLE; THYROID FUNCTION TESTS; VISION DISORDERS;

EID: 54349098013     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-008-1112-1     Document Type: Article

References (69)

1. Bartley GB, Fatourechi V, Kadrmas EF, et al. Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:426-34.
2. Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of Graves' orbitopathy vary with age and sex. Arch Ophthalmol 1993;111:197-201.
3. Ponto KA, Pitz S, Pfeiffer N, et al. Lebensqualität und berufliche Belastung bei endokriner Orbitopathie. Dtsch Ärztebl 2008:eingereicht.
4. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995;120:511-7.
5. Orgiazzi J. Pathogenesis. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:41-56.
6. Kahaly G, Förster G, Pitz S, et al. Aktuelle interdisziplinäre Diagnostik und Therapie der endokrinen Orbitopathie. Dtsch Med Wochenschr 1997;122:27-32.
7. Kalmann R, Mourits MP. Late recurrence of unilateral Graves orbitopathy on the contralateral side. Am J Ophthalmol 2002;133:727-9.
8. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91:3464-70.
9. Salvi M, Spaggiari E, Neri F, et al. The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement. J Clin Endocrinol Metab 1997;82:1027-30.
10. Molnar I, Balazs C. High circulating IL-6 levels in Graves' ophthalmopathy. Autoimmunity 1997;25:91-6.
11. Mourits MP. Diagnosis and differential diagnosis of Graves' orbitopathy. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:66-77.
12. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005;26:704-28.
13. Lazarus JH, Marino M. Orbit-thyroid relationship. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:27-33.
14. Förster G, Kahaly GJ. Rauchen und endokrine Orbitopathie. Dtsch Med Wochenschr 1997;122:1060-1.
15. Bartalena L, Martino E, Marcocci C, et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 1989;12:733-7.
16. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998;129:632-5.
17. Eckstein A, Quadbeck B, Mueller G, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 2003;87:773-6.
18. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax 1987;42:241-9.
19. Winsa B, Adami HO, Bergström R, et al. Stressful life events and Graves' disease. Lancet 1991;338:1475-9.
20. Yoshiuchi K, Kumano H, Nomura S, et al. Psychosocial factors influencing the short-term outcome of antithyroid drug therapy in Graves' disease. Psychosom Med 1998;60:592-6.
21. Saber E, McDonnell J, Zimmermann KM, et al. Extraocular muscle changes in experimental orbital venous stasis: some similarities to Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol 1996;234:331-6.
22. Sorsky A, Pardasani D, Gagnon A, et al. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996;81:3428-31.
23. Heufelder AE, Herterich S, Ernst G, et al. Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Eur J Endocrinol 1995;132:266-77.
24. Heufelder AE, Wenzel BE, Scriba PC. Antigen receptor variable region repertoires expressed by T cells infiltrating thyroid, retroorbital, and pretibial tissue in Graves' disease. J Clin Endocrinol Metab 1996;81:3733-9.
25. Feliciello A, Porcellini A, Ciullo I, et al. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 1993;342:337-8.
26. Paschke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995;42:565-9.
27. Otto E, Förster G, Kuhlemann K, et al. TSH receptor in endocrine autoimmunity. Clin Exp Rheumatol 1996;14:77-84.
28. Hiromatsu Y, Sato M, Inoue Y, et al. Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissue from patients with thyroid-associated ophthalmopathy. Thyroid 1996;6:553-62.
29. Crisp MS, Lane C, Halliwell M, et al. Thyrotropin receptor transcripts in human adipose tissue. J Clin Endocrinol Metab 1997;82:2003-5.
30. Major BJ, Cures JA, Frauman AG. The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: a link to the pathogenesis of Graves' ophthalmopathy. Biochem Biophys Res Commun 1997;230:493-6.
31. Burch HB, Sellitti D, Barnes SG, et al. Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1994;78:1384-91.
32. Kahaly G, Otto E, Förster G, et al. T cells and orbital connective tissue in endocrine orbitopathy. Exp Clin Endocrinol Diabetes 1996;104:79-84.
33. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000;52:267-71.
34. Wall JR, Hayes M, Scalise D, et al. Native gel electrophoresis and isoelectric focusing of a 64-kilodalton eye muscle protein shows that it is an important target for serum antibodies in patients with thyroid-associated ophthalmopathy and not expressed in other skeletal muscle. J Clin Endocrinol Metab 1995;80:1226-32.
35. Otto E, Ochs K, Hansen C, et al. Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens. J Clin Endocrinol Metab 1996;81:3045-50.
36. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995;42:45-50.
37. Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990;150:1098-101.
38. Weetman AP, Holt ME, Campbell AK, et al. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J (Clin Res Ed) 1984;288:518-20.
39. Benker G, Kahaly GJ, Reinwein D. What can the European Multicenter Trial on the treatment of Graves' disease with antithyroid drugs teach us about the course of thyroid-associated orbitopathy (TAO)? European Multicenter Trial Group. Exp Clin Endocrinol Diabetes 1999;107:Suppl 5:S186-9.
40. Eckstein A, Esser J. Endokrine Orbitopathie. Pathogenese, klinisches Bild und Untersuchung, stadienabhängige Therapie. Ophthalmologe 2003;100:857-80.
41. Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid 1997;7:241-5.
42. Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol 2002;120:380-6.
43. Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005;90:5234-40.
44. Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000;10:521.
45. Marinó M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004;14:403-6.
46. Salvi M, Vannucchi G, Sbrozzi F, et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 2004;14:631-4.
47. Le Moli R, Baldeschi L, Saeed P, et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 2007;17:357-62.
48. Gursoy A, Cesur M, Erdogan MF, et al. New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy. Endocrine 2006;29:513-6.
49. Kahaly GJ. Management of moderately severe Graves' orbitopathy. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:120-52.
50. Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986;16:415-22.
51. Kahaly G, Pitz S, Müller-Forell W, et al. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996;106:197-202.
52. Krassas GE, Kaltsas T, Dumas A, et al. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997;136:416-22.
53. Kung AW, Michon J, Tai KS, et al. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 1996;6:381-4.
54. Krassas GE, Kahaly GJ. The role of octreoscan in thyroid eye disease. Eur J Endocrinol 1999;140:373-5.
55. Spallholz JE, Boylan LM, Larsen HS. Advances in understanding selenium's role in the immune system. Ann N Y Acad Sci 1990;587:123-39.
56. Gärtner R, Gasnier BC, Dietrich JW, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 2002;87:1687-91.
57. Gärtner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors 2003;19:165-70.
58. Peretz A, Neve J, Duchateau J, et al. Adjuvant treatment of recent onset rheumatoid arthritis by selenium supplementation: preliminary observations. Br J Rheumatol 1992;31:281-2.
59. Kahaly GJ, Roesler HP, Kutzner J, et al. Radiotherapy for thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 1999;107:Suppl 5:S201-7.
60. Kahaly GJ, Rösler HP, Pitz S, et al. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000;85:102-8.
61. Pitz S, Kahaly G, Rösler HP, et al. Retrobulbäre Bestrahlung bei endokriner Orbitopathie - Erfahrungen im Langzeitverlauf. Klin Monatsbl Augenheilkd 2002;219:876-82.
62. Baldeschi L. Rehabilitative surgery. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:160-2.
63. Baldeschi L. Orbital decompression. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:163-76.
64. Kahaly GJ, Bumb P, Pitz S, et al. Operative Entlastung bei endokriner Orbitopathie. Med Klin 2007;102:714-9.
65. Esser J, Eckstein A. Ocular muscle and eyelid surgery in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 1999;107:Suppl 5:S214-21.
66. Nardi M. Eye muscle surgery. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:176-87.
67. Neoh C, Eckstein A. Eyelid surgery. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:188-200.
68. Morgenstern KE, Evanchan J, Foster JA, et al. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthal Plast Reconstr Surg 2004;20:181-5.
69. Wiersinga WM. Combined thyroid-eye clinics. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy - a multidisciplinary approach. Basel: Karger, 2007:96-9.